Precision Genomic Practice in Oncology: Pharmacist Role and Experience in an Ambulatory Care Clinic

• Main Authors: Farah Raheem (Author), Pauline Kim (Author), Meagan Grove (Author), Patrick J. Kiel (Author)
• Format: Book
• Published: MDPI AG, 2020-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2226-4787; 10.3390/pharmacy8010032
• Keywords: precision genomics; precision medicine; precision oncology; targeted therapy; oncology pharmacist; molecular tumor board; next generation sequencing; Pharmacy and materia medica; RS1-441
• Source: Pharmacy, Vol 8, Iss 1, p 32 (2020)

Recent advancements in molecular testing, the availability of cost-effective technology, and novel approaches to clinical trial design have facilitated the implementation of tumor genome sequencing into standard of care oncology practices. Current models of precision oncology practice include specialized clinics or consultation services based on a molecular tumor board (MTB) approach. MTBs are comprised of interprofessional teams of clinicians and scientists who evaluate tumors at the molecular level to guide patient-specific targeted therapy. The practice of precision oncology utilizing MTB-based models is an emerging approach, transforming precision genomics from a novel concept into clinical practice. This rapid shift in practice from cytotoxic therapy to targeted medicine poses challenges, yet brings exciting opportunities to clinical pharmacists practicing in hematology and oncology. Only a few precision genomics programs in the United States have a strong pharmacy presence with oncology pharmacists serving in leadership roles in research, interpreting genomic sequencing, making treatment recommendations, and facilitating off-label drug procurement. This article describes the experience of the precision medicine clinic at the Indiana University Health Simon Cancer Center, with emphasis on the role of the pharmacist in the precision oncology initiative.